ArticleTherapeutic advances in medical oncology2019

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.

Susanne Crocamo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.